hannes smarason: progress & prospects in genomics
TRANSCRIPT
Making Progress in Genomics: Reflections and Prospects
Hannes Smarason
Genome Sequencing |Personalized Medicine | Transforming Health Care
Reflections on the Past, Prospects for the Future
• The annual American Society of Human Genomics Meeting (ASHG 2016) provides an excellent opportunity to:– Take stock of our accomplishments over the last few years; and – Consider what we can achieve in the years ahead.
• Our accomplishments have been numerous and our goals are ambitious, yet achievable. At WuXi NextCODE, we perceive exciting opportunities for our field. As we move toward these goals, we will build on our successes and harness the power of genomics to revolutionize healthcare and improve patient outcomes.
What We Have Achieved
In recent years our work in genomics has been transforming medicine and improving patient outcomes in numerous ways. Consider these five highlights:
1. Improvements in Sequencing Technology and Analytical Tools– Dramatic increases in sequencing speed and efficiency are yielding an ever-‐increasing volume
of genomic data.– Novel methods of analysis, like the powerful genomics platform employed here at WuXi
NextCODE, have considerably advanced our understanding of genetic variations and their clinical significance.
2. Transformations in Cancer Treatment– The expanding use of genomic data to guide treatment decisions in oncology is dramatically
changing the way clinicians approach cancer care.– Our growing understanding of genetic predispositions for certain cancers is helping high-‐risk
individuals make informed choices about preventive care.
What We Have Achieved (Cont’d)
3. Progress in Rare Disease– Genomics has brought new hope to families struggling with rare diseases.– Genomic data shortens diagnostic odysseys, guides treatment, and helps patients, families,
and researchers build communities.
4. Empowerment of Patients and Consumers– Patients and consumers are increasingly informed about the innovative and meaningful ways
in which genomic data can guide healthcare decisions.– Successes in our field are empowering individuals to pursue personalized medicine and
generating interest in direct-‐to-‐consumer testing.
5. Innovations in Cloud-‐Based Analysis– The vast and ever-‐growing quantity of genomic data and related information has sparked new,
cloud-‐based approaches to storage and analysis.– WuXi NextCODE’s Exchange is at the forefront of the accelerated research made possible by
real-‐time collaboration and analysis in the cloud.
What We Can Achieve Our work in genomics will drive meaningful change over the next few years. Consider these five areas in which we can make significant progress:1. Effective Communication and Collaboration
– Realizing the full potential of big data and cloud-‐based computing will require new efforts to dismantle “data silos.”
– Recent initiatives in cancer research signify a willingness to share data to improve patient outcomes.
– We encourage researchers and clinicians throughout the field of genomics to promote communication among all stakeholders.
2. Policies for Research with Patient Data – Our field derives its greatest power from careful analysis of genomic data, and access to data is
critical to effecting meaningful change in healthcare.– In order to gather this game-‐changing data – from patients, from consumers, and from
population-‐wide studies – we need to develop and embrace policies that consider the ‘biorights’ of patients.
– We believe individuals who wish to contribute information for research should have the opportunity to do so, and encourage all parties to communicate clearly the purposes and extent of data-‐sharing.
What We Can Achieve (Cont’d)3. Integration for Clinical Trials
– As we move forward, clinical trials will increasingly:• Test the efficacy of treatments tailored to specific genetic anomalies; and• Use genetic information to screen participants.
– The use of genomics in clinical trials will dramatically accelerate the development of personalized therapies that will surely improve patient outcomes.
4. Actionable Information from Population-‐Wide Genomic Studies– Analysis of the data we are collecting around the world is an essential step to reshaping healthcare
practices worldwide.– In the near future we will reap significant rewards from projects that gather population-‐wide genomic
information.
5. Globalization of Genomic Products: ‘Think Globally, Act Locally’– The power of genomic information is now known across the globe, and can be applied in a multitude
of positive ways. – With such widespread potential, individual countries and cultures will choose to advance and roll-‐out
genomics in their own distinct ways for the benefit of their citizens. – Companies that develop genomic products will need to adapt and design their products for use in
specific markets. – At WuXi NextCODE, the first focus of our product portfolio for individual patients/families
is in China, where we are delivering three offerings: population-‐optimized diagnostics, carrier screening, and whole-‐genomic wellness scans.
Building on the Past, Driving the Future• Recent accomplishments in our field provide a solid foundation upon which we can
expand the data and analysis necessary for meaningful change in healthcare.• The genomic revolution in medicine that we envisage will be achieved through
applied use of research and development that is:– Fueled by big data, including data provided by informed consumers and patients and data
derived from population-‐wide studies; – Supported by clinical trials crafted to assess the safety and efficacy of treatments tailored
to individual characteristics; and– Enabled by collaborative work and effective communication.
• At WuXi NextCODE, we are energized by the prospects for genomics in the years to come. We are proud to be at the cutting edge, providing the tools and resources that researchers and clinicians need to harness the transformative power of genomic data. And we are confident that our field will continue to drive meaningful changes in healthcare that improve patient outcomes.